Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MD1003 in Hepatic Impaired Patients vs Healthy Subjects
NCT04252417Phase 1Terminated
- Sponsor
- MedDay Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 1, open-label trial of biotin in multiple sclerosis (MS) (2 arms), sponsored by MedDay Pharmaceuticals. Primary endpoints: Area under the curve from dosing time to last measurement at 168 hours, Area under the curve from dosing time to infinity at 168 hours and 2 more. Started Oct 2019; status: terminated.
02
Drugs
biotin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04252417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252417.